Systematic review on budegfort inhalation aerosol in treatment of chronic obstructive pulmonary disease
Jiang Ai-wen
Zhang Rui-xue
Zhao Xue-ping
Chen Li-ping
Pu Jie-kun
Du Pei-shan
Abstract：Objective To systematically evaluate the efficacy and safety of budegfort inhalation aerosol in the treatment of chronic obstructive pulmonary disease.Methods A search was performed in databases including PubMed,Clinical Trails.gov,CBM,CNKI,Wanfang and VIP to collect randomized controlled trials(RCT)of clinical efficacy and safety about budegfort inha-lation aerosol for COPD,the retrieval time was from database establishment to Jan.2024.After data extraction and quality evalua-tion,Meta-analysis was carried out by RevMan 5.3 statistical software.Results A total of 11 RCT including 3 113 patients were enrolled.Meta-analysis showed that the total effective rate(RR=1.12,95%CI=1.06-1.17,P<0.01),forced vital capacity(MD=0.37,95%CI=0.14-0.61,P=0.01),FEV1/FVC(MD=6.82,95%CI=4.23-9.40,P<0.01),CAT(MD=-4.29,95%CI=-7.22--1.37,P=0.004)and SGRQ score(MD=-7.12,95%CI=-12.46--1.77,P=0.009)in the budegfort inhalation aerosol group were higher than those in the control group,showing statistically significant differences.There were no significant differences in the FEV1(RR=1.00,95%CI=0.96-1.04,P=0.96),the incidence of adverse drug reactions(RR=1.13,95%CI=0.95-1.33,P=0.16)and serious adverse drug reactions(RR=0.64,95%CI=0.35-1.17,P=0.15)between the two groups.Conclusion Based on current evidence,budegfort inhalation aero-sol shows better clinical efficacy and comparable safety in the treatment of COPD.
Keywords：Budegfort inhalation aerosolChronic obstructive pulmonary diseaseMeta-analysis
Publication Date：2025-02-24
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 185-188 )